The Changing Game Plan for Acute Lymphoblastic Leukemia

The Changing Game Plan for Acute Lymphoblastic Leukemia

Emerging Treatment Options and Progressive Approaches to Patient Care

Not a member of My prIME? Join now for instant access.

Meeting Overview

Get the latest updates in acute lymphoblastic leukemia (ALL) at this interactive satellite symposium. A variety of topics will be discussed, including diagnostics and risk factors; the role of minimal residual disease in prognosis and treatment planning; optimal treatment strategies across varying patient populations, including those with Philadelphia chromosome (Ph)-positive ALL and elderly patients; as well as new and emerging therapies. Attendees will have the opportunity to interact with the expert faculty throughout the symposium.

Please note that due to congress restrictions, spots are limited and seats will be given on a first-come, first-served basis. Please arrive by 7.15 AM to guarantee your spot.

Friday Satellite Symposium on The Changing Game Plan for Acute Lymphoblastic Leukemia: Emerging Treatment Options and Progressive Approaches to Patient Care, preceding the 60th ASH Annual Meeting and Exposition.

Date and Location

Friday, November 30, 2018
7.00 AM – 7.30 AM – Breakfast and Registration
7.30 AM – 10.50 AM – Educational Session

Grand Ballrooms 5-6
Marriott Marquis San Diego Marina
333 W Harbor Dr
San Diego, California 92101



Friday, November 30, 2018



San Diego, California, United States



3 AMA PRA Category 1 Credits™

7.00 AM Tailgating before the game: Breakfast and registration
7.30 AM Welcome and introduction
Martin Tallman, MD
7.35 AM Pre-game analysis: Interactive audience quiz
Martin Tallman, MD
7.40 AM Sizing up the competition: Advances in risk assessment of ALL
Martin Tallman, MD
7.55 AM Audience Q & A
Martin Tallman, MD
8.00 AM Interactive case #1: Patient with Ph-positive ALL
Steven Coutre, MD
8.05 AM Studying the playbook for Ph-positive ALL
Steven Coutre, MD
8.25 AM Audience Q & A
Steven Coutre, MD
8.30 AM Interactive case #2: Older adult with relapsed Ph-negative ALL
Richard M. Stone, MD
8.35 AM Strategies for more “seasoned” players: Active treatment for older patients with relapsed/refractory ALL
Richard M. Stone, MD
8.50 AM Audience Q & A
Richard M. Stone, MD
8.55 AM Halftime break (coffee break)
9.10 AM
Interactive case #3: 50-year-old patient with Ph-negative ALL receiving initial multiagent chemotherapy
Steven Coutre, MD 
9.15 AM Driving toward the endzone: Minimal residual disease and post-remission therapy
Steven Coutre, MD
9.30 AM Audience Q & A
Steven Coutre, MD
9.35 AM Interactive case #4: 30-year-old patient with relapsed/refractory, Ph-negative ALL
Anthony Stein, MD
9.40 AM Game changers in the treatment of  relapsed/refractory ALL
Anthony Stein, MD
10.00 AM Audience Q & A
Anthony Stein, MD
10.05 AM Scouting for new players: Future directions in ALL
Nicholas Short, MD
10.25 AM Locker room huddle: Expert insight on practice challenges
Faculty panel discussion/audience participation
10.40 AM Post-game analysis: Interactive audience quiz and prIME Points™
Martin Tallman, MD
10.50 AM Adjourn


  • Martin Tallman, MDMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Faculty

  • Steven Coutre, MDStanford University
    Stanford, California, United States
  • Nicholas Short, MDMD Anderson Cancer Center
    Houston, Texas, United States
  • Anthony Stein, MDCity of Hope
    Duarte, California, United States
  • Richard M. Stone, MDDana-Farber Cancer Institute
    Boston, Massachusetts, United States

This activity is designed for hematologists, medical oncologists, and other healthcare professionals involved in the treatment of hematologic malignancies.

After successful completion of this educational activity, participants should be able to:

  • Interpret patient- and disease-related factors to accurately diagnose and assess risk in adolescents/young adults (AYAs) and adults with ALL
  • Describe the role of minimal residual disease assessment in both the prognosis and treatment planning for AYAs and adults with ALL
  • Select optimal treatment approaches for relapsed/refractory ALL, including in AYAs, adults, and elderly or unfit patients
  • Analyze the role of new and emerging therapies used to treat ALL in AYAs and adults
  • Design optimal treatment strategies for patients with Ph-positive and Ph-like ALL

This educational activity is supported by grants from Amgen and Takeda Oncology.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Sunshine Act/EFPIA Statement

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Americans With Disabilities Act

Event staff will be glad to assist you with any special needs (physical, dietary, etc). Please contact Emily Simpson prior to the live event at 678.686.7762.

There is no fee for this activity.


Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.